Altamira Therapeutics Completes Patient Enrollment in House Dust Mite Allergy Trial with Bentrio

Rhea-AI Summary

Altamira Therapeutics Ltd. (NASDAQ:CYTO) has completed patient enrollment in its Bentrio™ trial for house dust mite (HDM) allergic rhinitis, involving 37 patients. The trial aims to assess Bentrio's efficacy in treating perennial allergic rhinitis under controlled HDM exposure, with top-line results expected in Q2 2022. The company's CEO emphasized the importance of Bentrio, following positive outcomes in previous studies. Notably, HDM allergies affect millions globally and can severely impact quality of life.

Positive

• Completion of patient enrollment in Bentrio trial, indicating progress in clinical development.
• Expectations for positive top-line results in Q2 2022, which could boost stock confidence.
• Bentrio is gaining traction as a drug-free option for allergy sufferers, potentially expanding market reach.

Negative

• Uncertainty regarding the trial outcomes could impact investor sentiment.
• Dependence on future funding for continued product development and commercialization.

HAMILTON, BERMUDA / ACCESSWIRE / March 15, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced completion of patient enrollment in its Bentrio™ trial in house dust mite ("HDM") allergic rhinitis. The Company expects to release top-line results from the trial during the second quarter of 2022.

The trial, which enrolled a total of 37 patients with a history of perennial allergic rhinitis ("PAR") caused by HDM exposure, is designed to evaluate the efficacy of Bentrio™ in the treatment of PAR in an environmental exposure chamber (EEC), i.e. under controlled HDM exposure. Study participants were randomized under an open label, three-period crossover design to receive either Bentrio™ in a single or double dose or no treatment prior to HDM exposure for three hours. The primary endpoint will be the change in the Total Nasal Symptom Score (TNSS) from baseline. The trial is being conducted at a single study site in Canada.

"House dust mite allergies are a very common problem, especially in more humid geographies, and can cause serious suffering and reduced quality of life," commented Thomas Meyer, Altamira Therapeutics' founder, Chairman and CEO. "Following the positive outcomes from our previous clinical investigation of Bentrio in grass pollen allergic rhinitis, we expect this new study to add to the growing body of evidence demonstrating Bentrio's protective effects against multiple airborne allergens. In the meantime, we continue with the commercial roll-out of Bentrio, helping to provide relief for those many allergy sufferers who have been looking for an effective treatment without any drug or preservative ingredients."

About House Dust Mite Allergies

HDM allergens constitute the prime cause of respiratory allergies (i.e. allergic rhinitis and allergic asthma), with prevalence estimates for allergen sensitization ranging between 65 and 130 million persons in the general population worldwide, or as many as 50% among asthmatic patients.¹ In the US population aged 6 years and older, dust mite allergens are the second most common source of sensitization right after plant-related allergens (20.3 and 27.1%, respectively).² Unlike plant-related allergens, which tend to be seasonal (e.g. pollen / hay fever), HDMs may be present all year long. Symptoms of HDM allergies include sneezing, a runny or stuffy nose, itching, coughing, difficulty breathing, chest tightness or pain.

References

¹Calderon et al. (2015), Respiratory allergy caused by house dust mites: What do we really know?, J Allergy Clin Immunol 136(1):38-48.

²Salo et al. (2014), Prevalence of allergic sensitization in the United States: results from the National Health and Nutrition Examination Survey (NHANES) 2005-2006. J Allergy Clin Immunol 134(2):350-9.

About Bentrio™

Bentrio™ (AM-301) is a drug-free nasal spray intended for personal protection against airborne viruses and allergens. Upon application into the nose, Bentrio™ forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of viruses or allergens with cells; in addition, the composition serves to bind such particles and help with their discharge and to humidify the nasal mucosa. Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms.

About Altamira Therapeutics

Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio™; commercial) or for the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®; Phase 3). The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol "CYTO".

Forward-looking Statements

This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval and timing of commercialization of AM-301, Altamira Therapeutics' need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira Therapeutics' product candidates, the clinical utility of Altamira Therapeutics' product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics' intellectual property position and Altamira Therapeutics' financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira Therapeutics' capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2020, and in Altamira Therapeutics' other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

Investor contact:
Stephen Kilmer
646.274.3580
sjk@altamiratherapeutics.com

SOURCE: Altamira Therapeutics

View source version on accesswire.com:
https://www.accesswire.com/693111/Altamira-Therapeutics-Completes-Patient-Enrollment-in-House-Dust-Mite-Allergy-Trial-with-Bentrio

FAQ

What is the recent news about Altamira Therapeutics (CYTO)?

Altamira Therapeutics announced the completion of patient enrollment in its Bentrio trial for house dust mite allergic rhinitis.

When will the results of the Bentrio trial be released?

Top-line results from the Bentrio trial are expected in Q2 2022.

How many patients were enrolled in the Bentrio trial?

A total of 37 patients were enrolled in the Bentrio trial.

What is Bentrio designed to treat?

Bentrio is a drug-free nasal spray intended to protect against airborne allergens, specifically targeting allergic rhinitis caused by house dust mites.

Why are house dust mites significant for allergy sufferers?

House dust mite allergies are common and can severely impact the quality of life for many individuals, affecting millions worldwide.